JP2019509351A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509351A5
JP2019509351A5 JP2019500746A JP2019500746A JP2019509351A5 JP 2019509351 A5 JP2019509351 A5 JP 2019509351A5 JP 2019500746 A JP2019500746 A JP 2019500746A JP 2019500746 A JP2019500746 A JP 2019500746A JP 2019509351 A5 JP2019509351 A5 JP 2019509351A5
Authority
JP
Japan
Prior art keywords
therapy
administration
active substance
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509351A (ja
JP7048571B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/023676 external-priority patent/WO2017165571A1/en
Publication of JP2019509351A publication Critical patent/JP2019509351A/ja
Publication of JP2019509351A5 publication Critical patent/JP2019509351A5/ja
Priority to JP2022047991A priority Critical patent/JP7528143B2/ja
Application granted granted Critical
Publication of JP7048571B2 publication Critical patent/JP7048571B2/ja
Priority to JP2024118592A priority patent/JP2024156736A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500746A 2016-03-22 2017-03-22 毒性を予防または改善するための早期介入法 Active JP7048571B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022047991A JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662311906P 2016-03-22 2016-03-22
US62/311,906 2016-03-22
US201662417287P 2016-11-03 2016-11-03
US62/417,287 2016-11-03
US201662429722P 2016-12-02 2016-12-02
US62/429,722 2016-12-02
PCT/US2017/023676 WO2017165571A1 (en) 2016-03-22 2017-03-22 Early intervention methods to prevent or ameliorate toxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022047991A Division JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法

Publications (3)

Publication Number Publication Date
JP2019509351A JP2019509351A (ja) 2019-04-04
JP2019509351A5 true JP2019509351A5 (cg-RX-API-DMAC7.html) 2020-04-30
JP7048571B2 JP7048571B2 (ja) 2022-04-05

Family

ID=58609964

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019500746A Active JP7048571B2 (ja) 2016-03-22 2017-03-22 毒性を予防または改善するための早期介入法
JP2022047991A Active JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A Pending JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022047991A Active JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A Pending JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Country Status (13)

Country Link
US (5) US11518814B2 (cg-RX-API-DMAC7.html)
EP (3) EP3433276B1 (cg-RX-API-DMAC7.html)
JP (3) JP7048571B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190021200A (cg-RX-API-DMAC7.html)
CN (1) CN109476743A (cg-RX-API-DMAC7.html)
AU (2) AU2017238218B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018069251A2 (cg-RX-API-DMAC7.html)
CA (1) CA3018588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907557T3 (cg-RX-API-DMAC7.html)
MA (2) MA71266A (cg-RX-API-DMAC7.html)
MX (1) MX2018011480A (cg-RX-API-DMAC7.html)
RU (1) RU2018136877A (cg-RX-API-DMAC7.html)
WO (1) WO2017165571A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2016064929A1 (en) 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
ES2901795T3 (es) 2015-12-04 2022-03-23 Juno Therapeutics Inc Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
WO2017165571A1 (en) 2016-03-22 2017-09-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Early intervention methods to prevent or ameliorate toxicity
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
CA3045355A1 (en) * 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
CN110582287A (zh) 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 与在细胞疗法中给药有关的组合物、制品和方法
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US20210198372A1 (en) * 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN112055595B (zh) 2018-01-22 2024-12-17 恩多塞特公司 Car t细胞的使用方法
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CN119770648A (zh) * 2018-03-09 2025-04-08 克莱格医学有限公司 用于治疗肿瘤的方法和组合物
EP3762012A1 (en) * 2018-03-09 2021-01-13 Ospedale San Raffaele S.r.l. Il-1 antagonist and toxicity induced by cell therapy
US20210263045A1 (en) * 2018-04-06 2021-08-26 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
BR112022001896A2 (pt) * 2019-08-14 2022-06-21 Rigel Pharmaceuticals Inc Método para bloquear ou atenuar síndrome de liberação de citocinas
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
WO2022072515A1 (en) * 2020-09-29 2022-04-07 Washington University Methods to determine risk of neurotoxicity
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
IL308216A (en) 2021-05-03 2024-01-01 Incyte Corp Jak1 pathway inhibitors for the treatment of prurigo nodularis

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US265209A (en) 1882-09-26 Automatic feeder for perforators
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (cg-RX-API-DMAC7.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE68919715T2 (de) 1988-12-28 1995-04-06 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
JPH09505721A (ja) 1992-10-20 1997-06-10 シータス オンコロジー コーポレイション インターロイキン６レセプターアンタゴニスト
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20090175879A1 (en) * 2006-06-22 2009-07-09 Cellact Pharma Gmbh Novel target in the treatment of cytokine release syndrome
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8747290B2 (en) 2007-12-07 2014-06-10 Miltenyi Biotec Gmbh Centrifuge for separating a sample into at least two components
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
ES2618586T3 (es) * 2010-09-16 2017-06-21 Baliopharm Ag Anticuerpo anti-huTNFR1
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN107880101B (zh) 2011-11-11 2021-12-21 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2018130123A (ru) 2012-05-03 2018-11-07 Фред Хатчинсон Кансэр Рисёч Сентер Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
EA201590210A1 (ru) * 2012-07-13 2015-08-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов
IL237315B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
IL297418B2 (en) * 2015-02-18 2023-11-01 Enlivex Therapeutics Rdo Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
WO2017165571A1 (en) 2016-03-22 2017-09-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Early intervention methods to prevent or ameliorate toxicity
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor

Similar Documents

Publication Publication Date Title
JP2019509351A5 (cg-RX-API-DMAC7.html)
Shimba et al. Pleiotropic effects of glucocorticoids on the immune system in circadian rhythm and stress
JP2024156736A5 (cg-RX-API-DMAC7.html)
Newton et al. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases
Mesquida et al. Interleukin-6 blockade in ocular inflammatory diseases
Silverman et al. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection
Canna et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Shoenfeld et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008
AU2017238218A1 (en) Early intervention methods to prevent or ameliorate toxicity
JP2021102644A5 (cg-RX-API-DMAC7.html)
Kasapçopur et al. Treatment in juvenile rheumatoid arthritis and new treatment options
Piccinni et al. Medroxyprogesterone acetate decreases Th1, Th17, and increases Th22 responses via AHR signaling which could affect susceptibility to infections and inflammatory disease
JP2019504892A5 (cg-RX-API-DMAC7.html)
JP2020530831A5 (cg-RX-API-DMAC7.html)
JP2017523187A5 (cg-RX-API-DMAC7.html)
US20170246217A1 (en) Use of cord blood plasma to treat nk cell-mediated diseases and ifn-γ mediated diseases
Everaerdt et al. Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice.
Bellmann et al. A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model
Rathinam et al. Dupilumab in the treatment of moderate to severe asthma: an evidence-based review
Alten et al. Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches
Xiao et al. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
Khan et al. Interleukin inhibitors and the associated risk of candidiasis
Spies et al. Prednisone chronotherapy
Joks et al. Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs